亚太地区医用酶技术市场预测至 2028 年 - COVID-19 影响和按酶类型(消化酶、溶栓酶、水解酶和核酸内切酶)进行的区域分析;应用(疾病治疗、诊断工具、生物医学研究等)

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 177    |    Report Code: TIPRE00025046    |    Category: Life Sciences

Asia Pacific Medical Enzyme Technology Market

市场介绍

酶是植物、动物和微生物的活细胞中产生的蛋白质。所有生物体都需要酶来生长以及产生和利用生命所必需的能量。在活细胞中,酶充当催化剂,加速控制生命过程的化学反应。一百多年来,酶一直是重要的工业产品。然而,潜在的应用范围正在迅速扩大。随着重组 DNA 技术的出现,大量生产以前稀有的酶已成为可能,从而降低了成本。此外,在药品制造中,制造手性纯化合物的愿望正在带来新的机遇。技术进步促进了酶在越来越广泛的工艺条件下的使用。

因此,研究和开发活动的显着增加预计将在未来几年对医用酶技术产生巨大需求,预计这将进一步推动医用酶技术市场。

在武汉发生一系列肺炎病例后,中国湖北省省会城市卫生部门于 2020 年 1 月宣布这些病例由一种新型冠状病毒引起,正式名称为极端急性呼吸综合征冠状病毒(SARS-CoV)-2。在中国武汉爆发初期,发现了出现消化系统症状的 COVID-19 患者。在一项涉及 204 名 COVID-19 患者并经过实验室测试验证的描述性横断面多中心研究中,41.6% 的 COVID-19 患者报告恶心或呕吐,17.2% 报告腹泻。重要的是,患有严重疾病的患者比患有轻微疾病的患者更容易出现腹泻、恶心或呕吐。武汉一家医院的另一项单中心研究发现,消化系统症状与 COVID-19 的严重程度密切相关。入住重症监护病房 (ICU) 的患者比未转入 ICU 的患者更常见腹泻、恶心、呕吐、胃痛和厌食,并且两组之间厌食症的患病率具有统计学意义,这表明它可能是严重疾病的有力预测因子。因此,消化酶需求的增加是由于 COVID-19 病例的增加推动了预测期内市场的增长。

 

市场概况与动态

亚太地区医用酶技术市场预计将从 854.1 美元增长2021 年为 100 万美元,到 2028 年将达到 13.856 亿美元;预计 2021 年至 2028 年复合年增长率为 7.2%。酶是各种疾病状态的首选标记物,例如心肌梗塞、黄疸、胰腺炎、癌症和神经退行性疾病。它们通过诊断、预后和反应治疗评估来深入了解疾病过程。此外,许多酶在医疗中用作诊断试剂。由于酶独特的特异性、催化效率高、作用条件温和等特点,酶法诊断已成为一种可靠、简单、快速的诊断方法。药用酶因其疗效显着、副作用小等特点,在医疗保健领域的应用越来越广泛,带动了药用酶技术市场的发展。

 

主要细分市场

从酶类型来看,水解酶细分市场在2020年亚太医用酶技术市场中占据最大份额。从应用来看,疾病治疗领域占据2020年亚太医用酶技术市场最大份额。

 

 

主要来源和上市公司

准备本医用酶技术市场报告时参考的一些主要一手和二手来源亚太地区包括公司网站、年度报告、财务报告、国家政府文件、统计数据库等。报告中列出的主要公司包括 Merck Kgaa、Thermo Fisher Scientific Inc.、Novozymes、Takeda Pharmaceutical Company Limited、Agilent Technologies, Inc.、Genzyme Corporation、Asahi Kasei Corporation、Promega Corporation、Cytiva 和 Amano Enzyme Inc.

 

< span>购买报告的理由

  • 了解亚太地区医用酶技术市场格局并确定最有可能的细分市场确保丰厚的回报
  • 了解亚太地区医学酶技术市场不断变化的竞争格局,保持领先地位
  • 有效规划亚太地区的并购和合作交易通过识别最有希望销售的细分市场来了解医用酶技术市场
  • 通过对亚太地区医用酶技术市场各个细分市场的市场表现进行敏锐和全面的分析,帮助做出明智的业务决策
  • < li>获取亚太地区各细分市场2021-2028年的市场收入预测

 

亚太地区医用酶技术市场细分

按酶类型

  • 消化酶
    • L-天冬酰胺酶
    • 乳糖酶
    • 其他
  • 溶栓酶
    • 链激酶
    • 尿激酶< /span>
    • 其他
  • 水解酶
    • 透明质酸酶
    • 溶菌酶
    • 其他
  • 核酸内切酶
    • Benzonase
    • 其他

 

按应用

  • 疾病治疗
  • < li>诊断工具
  • 生物医学研究
  • 其他

 

按国家/地区

  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚
    • 亚太地区其他地区
< p>

 

提及的公司

  1. Merck Kgaa
  2. Thermo Fisher Scientific Inc .
  3. Novozymes
  4. 武田制药有限公司
  5. 安捷伦科技公司
  6. Genzyme Corporation
  7. 旭化成公司
  8. Promega公司
  9. Cytiva
  10. 天野酶公司

 

  ;

 

Asia Pacific Medical Enzyme Technology Strategic Insights

Strategic insights for Asia Pacific Medical Enzyme Technology involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-medical-enzyme-technology-market-strategic-framework.webp
Get more information on this report

Asia Pacific Medical Enzyme Technology Report Scope

Report Attribute Details
Market size in 2021 US$ 854.1 Million
Market Size by 2028 US$ 1,385.6 Million
Global CAGR (2021 - 2028) 7.2%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By 酶类型
  • 消化酶
  • 血栓溶解酶
  • 水解酶
  • 核酸内切酶
By 应用
  • 疾病治疗
  • 诊断工具
  • 生物医学研究
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Merck Kgaa
  • Thermo Fisher Scientific Inc.
  • Novozymes
  • Takeda Pharmaceutical Company Limited
  • Agilent Technologies, Inc.
  • Genzyme Corporation
  • Asahi Kasei Corporation
  • Promega Corporation
  • Cytiva
  • Amano Enzyme Inc.
  • Get more information on this report

    Asia Pacific Medical Enzyme Technology Regional Insights

    The regional scope of Asia Pacific Medical Enzyme Technology refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-medical-enzyme-technology-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Medical Enzyme Technology Market

    1. Merck Kgaa
    2. Thermo Fisher Scientific Inc.
    3. Novozymes
    4. Takeda Pharmaceutical Company Limited
    5. Agilent Technologies, Inc.
    6. Genzyme Corporation
    7. Asahi Kasei Corporation
    8. Promega Corporation
    9. Cytiva
    10. Amano Enzyme Inc.        

     

    Frequently Asked Questions
    How big is the Asia Pacific Medical Enzyme Technology Market?

    The Asia Pacific Medical Enzyme Technology Market is valued at US$ 854.1 Million in 2021, it is projected to reach US$ 1,385.6 Million by 2028.

    What is the CAGR for Asia Pacific Medical Enzyme Technology Market by (2021 - 2028)?

    As per our report Asia Pacific Medical Enzyme Technology Market, the market size is valued at US$ 854.1 Million in 2021, projecting it to reach US$ 1,385.6 Million by 2028. This translates to a CAGR of approximately 7.2% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Medical Enzyme Technology Market report typically cover these key segments-

  • 酶类型 (消化酶, 血栓溶解酶, 水解酶, 核酸内切酶)
  • 应用 (疾病治疗, 诊断工具, 生物医学研究)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Medical Enzyme Technology Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Medical Enzyme Technology Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Medical Enzyme Technology Market?

    The Asia Pacific Medical Enzyme Technology Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Merck Kgaa
  • Thermo Fisher Scientific Inc.
  • Novozymes
  • Takeda Pharmaceutical Company Limited
  • Agilent Technologies, Inc.
  • Genzyme Corporation
  • Asahi Kasei Corporation
  • Promega Corporation
  • Cytiva
  • Amano Enzyme Inc.
  • Who should buy this report?

    The Asia Pacific Medical Enzyme Technology Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Medical Enzyme Technology Market value chain can benefit from the information contained in a comprehensive market report.